• Novartis AG, of Basel, Switzerland, is acquiring specialty dermatology generics company Fougera Pharmaceuticals Inc., of Melville, N.Y., from a Nordic Capital-led consortium for nearly $1 .53 billion in cash. Fougera will become part of Sandoz, Novartis' generic drug division.